-------------------------------------------------- ------
IACM-Bulletin of 31 March 2010
-------------------------------- ------------------------
* UK / Spain: expected shortly
Sativex is approved for the treatment of spasticity in multiple sclerosis
* Science: Promising results of a clinical study with
Sativex cannabis extract in the treatment of cancer pain
* USA: Californians will decide in November on the legalization of cannabis
1.
UK / Spain: expected shortly
Sativex is approved for the treatment of spasticity in multiple sclerosis
is expected to Sativex, the cannabis-based medicine
for diseases such as multiple sclerosis, get
approval for marketing in Britain and Spain
in the second quarter 2010, its manufacturer said
GW Pharmaceuticals on 18 March. The company said that the authorities of both countries
gave concluding
issues related to quality, safety and efficacy.
Talks now focus on issues such as the production of patient information leaflet
.
The drug, which is administered under the tongue spray,
will be marketed in the UK by the German company Bayer
and the rest of Europe by the English Almirall. GW
get 10 million pounds (15 billion U.S.
) as payment for Bayer by a British license, while Almirall pay
en España otros 2'5 millones de
libras cuando consiga la licencia de aprobación y se estipule su
precio. Los ensayos clínicos han demostrado que el Sativex
reduce la espasticidad en pacientes con esclerosis múltiple que no
responden adecuadamente a los tratamientos disponibles. GW
esperaba inicialmente conseguir la aprobación de su medicamento
en 2003, pero una serie de retrasos legales en Europa han
dificultado el proceso. Los analistas estiman picos de ventas de
Sativex en la esclerosis múltiple en aproximadamente 50-100
millones de libras al año.
Más información en:
http://www.reuters.com/article/idUSLDE62H0A420100318
http://www.gwpharm.com/Sativex % 20Regulatory% 20% 20%
20Update.aspx
(Source: GW Pharmaceuticals of March 18, 2010, Reuters
of March 18, 2010)
2.
Science: Promising results of a clinical study with
Sativex cannabis extract in the treatment of cancer pain
March 23 GW Pharmaceuticals announced preliminary results
Phase II study evaluating the efficacy and
safety of Sativex in the treatment of pain in patients with advanced cancer
not getting adequate analgesia with a right
chronic treatment with opioids. This trial was conducted by GW
along with licensing partner for Sativex in the United States
, Otsuka Pharmaceutical.
principal investigator was Dr. Russell K. Portenoy, Chairman of
Department of Pain Medicine and Palliative Care at Beth Israel Medical Center
New York.
preliminary results show that the study met its objectives and provided fundamental
efficacy and safety data that supports
advance to Phase III clinical trial.
This randomized double-blind, placebo-controlled, parallel
groups included a total of 360 patients
14 countries in North America, Europe, Latin America and Sudáfrica, y evaluó
tres rangos de dosis de extracto de cannabis, mientras que los
pacientes permanecieron con dosis estables y óptimas de fondo de
tratamiento con opiáceos durante el estudio. La medida principal
de eficacia del ensayo fue una evaluación por parte del paciente
del dolor en una escala de 0 a 10, que fue analizado utilizando tres
metodologías convencionales. Dos de los tres análisis mostraron
resultados estadísticamente significativos a favor del Sativex. Por
ejemplo, el cambio en la puntuación media del dolor desde la basal
mostró una diferencia estadísticamente significativa entre el grupo
al que se le administró dosis baja de Sativex and placebo. The
groups of low and medium doses of Sativex, when combined,
were also statistically better than placebo.
More information:
http://www.gwpharm.com/Phase 20IIb 20Cancer%%%%% 20Data.aspx 20Trial
20Pain
(Source: GW Pharmaceuticals of March 23, 2010)
3 . U.S.
: Californians will decide in November on the legalization of cannabis
California will again spearhead the debate on the legalization of cannabis
since, the authorities said
March 24, the issue will be included in the next
November referendum. County election officials
of Los Angeles presented its official estimate
valid signatures collected in that county after the state initiative legalizing
, so that these amount to more than 433,971
necessary to include the question in the referendum, Los Angeles Times said
.
The initiative would allow people over age 21 have
up to one ounce (28.5 grams) of cannabis for personal use. The
surveys indicate that most California voters
favor of legalization. Chris Lehane, one of the
responsible for the initiative, said voters "and accept"
that cannabis is commonplace. "They want to see
smart strategy," he added. John Lovell, a lobbyist
contrary to the law enforcement, said he believes voters will reject the proposition
. "Why the hell you want to add another substance that alters the mind
the legal arsenal," he asked.
(Source: UPI's March 24, 2010)
4. News in brief
*** USA: Arizona
In November, Arizonans will decide on the
legalization of cannabis for therapeutic purposes. One proposal would allow consumption
medical prescription of cannabis for relief
certain medical situations and
would create a network of nonprofit shops would sell the plant. The vote
initiative also contains provisions against discrimination
, including one that says an employer can not fire someone
found positive for cannabis
unless the company can prove that the person had consumed at work or
was "concerned" for the day labor
. (Source: Arizona Daily Star of March 19, 2010)
*** USA: Rhode Island
In total there are 355 doctors in Rhode Island who have signed for it
least one of their patients, the state form
necessary for the Department of Health issued a card
use marijuana. But 21 of those doctors are responsible for more
a third of the 1,347 cards issued medical cannabis
so far. (Source: The Providence Journal March 12
2010)
*** USA: South Dakota South Dakota
vote on the legalization of cannabis consumption
in treating pain, nausea and other
health problems. The secretariat of the state office has
accepted the request to include the question in the next consultation
November state election. (Source: www.chadrad.com )
*** Science: Depression
Animal Research conducted at the University of
Mississippi, USA, show that THC, CBD (cannabidiol)
and CSC (cannabichromene) have antidepressant effects. The
authors note that "can contribute to elevating effect
general mood of cannabis." (Source: El-Alfy AT, et al.
Pharmacol Biochem Behav 2010 Mar 20 [Electronic publication ahead of print]) *** Science
: Atherosclerosis
According to studies conducted at the University of Shanghai, China
a synthetic cannabinoid (WIN55 ,212-2) induction
reduces inflammation TNF-alpha
oxidation of LDL (bad cholesterol).
This effect was mediated by the CB2 receptor.
Researchers say these results indicate that "the CB2 receptor may be a novel
Drug Target
treatment of atherosclerosis." (Source: Hao MX, et al. J Lipid Res 2010 Mar
20. [Electronic publication ahead of print])
*** Science: Pain
According to research with diabetic mice, both
CB1 receptor agonists as CB2 reduce the development
painful diabetic peripheral neuropathy. (Source:
Toth CC, et al. Mol Pain 2010, 6 (1): 16.)
*** Science: Cancer
According to studies conducted at the Catholic University of
Korea, Seoul, a synthetic cannabinoid (in WIN55 ,212-2) inhibits the proliferation of human cells
of stomach cancer in a dose
-dependent effect mediated by the CB1 receptor
. (Source: Xi'an XS, et al. J Cell Biochem 2010 Mar
24. [Electronic publication ahead of print]).
International Association for Cannabinoid Medicines
(IACM)
Am
Mildenweg 6 D-59602 Germany Ruether
Phone: +49 (0) 2952-9708571
Fax: +49 (0) 2952-902651
Email: Info@cannabis-med.org
http://www.cannabis-med.org
To unsubscribe or discharge the mailing list
Bulletin of the IACM, or if you change your address e-mail, please visit
www.cannabis-med.org/spanish/subscribe.htm .
can choose different languages \u200b\u200b(English, German, French, Dutch, Italian and English
).
items taken from the Bulletin of the IACM
can be printed, translated and distributed freely for any purpose
noncommercial, provided the original work is properly cited
. The source of the Bulletin the IACM is
"IACM, www.cannabis-med.org ."
-------------------------------- ------------------------
* UK / Spain: expected shortly
Sativex is approved for the treatment of spasticity in multiple sclerosis
* Science: Promising results of a clinical study with
Sativex cannabis extract in the treatment of cancer pain
* USA: Californians will decide in November on the legalization of cannabis
1.
UK / Spain: expected shortly
Sativex is approved for the treatment of spasticity in multiple sclerosis
is expected to Sativex, the cannabis-based medicine
for diseases such as multiple sclerosis, get
approval for marketing in Britain and Spain
in the second quarter 2010, its manufacturer said
GW Pharmaceuticals on 18 March. The company said that the authorities of both countries
gave concluding
issues related to quality, safety and efficacy.
Talks now focus on issues such as the production of patient information leaflet
.
The drug, which is administered under the tongue spray,
will be marketed in the UK by the German company Bayer
and the rest of Europe by the English Almirall. GW
get 10 million pounds (15 billion U.S.
) as payment for Bayer by a British license, while Almirall pay
en España otros 2'5 millones de
libras cuando consiga la licencia de aprobación y se estipule su
precio. Los ensayos clínicos han demostrado que el Sativex
reduce la espasticidad en pacientes con esclerosis múltiple que no
responden adecuadamente a los tratamientos disponibles. GW
esperaba inicialmente conseguir la aprobación de su medicamento
en 2003, pero una serie de retrasos legales en Europa han
dificultado el proceso. Los analistas estiman picos de ventas de
Sativex en la esclerosis múltiple en aproximadamente 50-100
millones de libras al año.
Más información en:
http://www.reuters.com/article/idUSLDE62H0A420100318
http://www.gwpharm.com/Sativex % 20Regulatory% 20% 20%
20Update.aspx
(Source: GW Pharmaceuticals of March 18, 2010, Reuters
of March 18, 2010)
2.
Science: Promising results of a clinical study with
Sativex cannabis extract in the treatment of cancer pain
March 23 GW Pharmaceuticals announced preliminary results
Phase II study evaluating the efficacy and
safety of Sativex in the treatment of pain in patients with advanced cancer
not getting adequate analgesia with a right
chronic treatment with opioids. This trial was conducted by GW
along with licensing partner for Sativex in the United States
, Otsuka Pharmaceutical.
principal investigator was Dr. Russell K. Portenoy, Chairman of
Department of Pain Medicine and Palliative Care at Beth Israel Medical Center
New York.
preliminary results show that the study met its objectives and provided fundamental
efficacy and safety data that supports
advance to Phase III clinical trial.
This randomized double-blind, placebo-controlled, parallel
groups included a total of 360 patients
14 countries in North America, Europe, Latin America and Sudáfrica, y evaluó
tres rangos de dosis de extracto de cannabis, mientras que los
pacientes permanecieron con dosis estables y óptimas de fondo de
tratamiento con opiáceos durante el estudio. La medida principal
de eficacia del ensayo fue una evaluación por parte del paciente
del dolor en una escala de 0 a 10, que fue analizado utilizando tres
metodologías convencionales. Dos de los tres análisis mostraron
resultados estadísticamente significativos a favor del Sativex. Por
ejemplo, el cambio en la puntuación media del dolor desde la basal
mostró una diferencia estadísticamente significativa entre el grupo
al que se le administró dosis baja de Sativex and placebo. The
groups of low and medium doses of Sativex, when combined,
were also statistically better than placebo.
More information:
http://www.gwpharm.com/Phase 20IIb 20Cancer%%%%% 20Data.aspx 20Trial
20Pain
(Source: GW Pharmaceuticals of March 23, 2010)
3 . U.S.
: Californians will decide in November on the legalization of cannabis
California will again spearhead the debate on the legalization of cannabis
since, the authorities said
March 24, the issue will be included in the next
November referendum. County election officials
of Los Angeles presented its official estimate
valid signatures collected in that county after the state initiative legalizing
, so that these amount to more than 433,971
necessary to include the question in the referendum, Los Angeles Times said
.
The initiative would allow people over age 21 have
up to one ounce (28.5 grams) of cannabis for personal use. The
surveys indicate that most California voters
favor of legalization. Chris Lehane, one of the
responsible for the initiative, said voters "and accept"
that cannabis is commonplace. "They want to see
smart strategy," he added. John Lovell, a lobbyist
contrary to the law enforcement, said he believes voters will reject the proposition
. "Why the hell you want to add another substance that alters the mind
the legal arsenal," he asked.
(Source: UPI's March 24, 2010)
4. News in brief
*** USA: Arizona
In November, Arizonans will decide on the
legalization of cannabis for therapeutic purposes. One proposal would allow consumption
medical prescription of cannabis for relief
certain medical situations and
would create a network of nonprofit shops would sell the plant. The vote
initiative also contains provisions against discrimination
, including one that says an employer can not fire someone
found positive for cannabis
unless the company can prove that the person had consumed at work or
was "concerned" for the day labor
. (Source: Arizona Daily Star of March 19, 2010)
*** USA: Rhode Island
In total there are 355 doctors in Rhode Island who have signed for it
least one of their patients, the state form
necessary for the Department of Health issued a card
use marijuana. But 21 of those doctors are responsible for more
a third of the 1,347 cards issued medical cannabis
so far. (Source: The Providence Journal March 12
2010)
*** USA: South Dakota South Dakota
vote on the legalization of cannabis consumption
in treating pain, nausea and other
health problems. The secretariat of the state office has
accepted the request to include the question in the next consultation
November state election. (Source: www.chadrad.com )
*** Science: Depression
Animal Research conducted at the University of
Mississippi, USA, show that THC, CBD (cannabidiol)
and CSC (cannabichromene) have antidepressant effects. The
authors note that "can contribute to elevating effect
general mood of cannabis." (Source: El-Alfy AT, et al.
Pharmacol Biochem Behav 2010 Mar 20 [Electronic publication ahead of print]) *** Science
: Atherosclerosis
According to studies conducted at the University of Shanghai, China
a synthetic cannabinoid (WIN55 ,212-2) induction
reduces inflammation TNF-alpha
oxidation of LDL (bad cholesterol).
This effect was mediated by the CB2 receptor.
Researchers say these results indicate that "the CB2 receptor may be a novel
Drug Target
treatment of atherosclerosis." (Source: Hao MX, et al. J Lipid Res 2010 Mar
20. [Electronic publication ahead of print])
*** Science: Pain
According to research with diabetic mice, both
CB1 receptor agonists as CB2 reduce the development
painful diabetic peripheral neuropathy. (Source:
Toth CC, et al. Mol Pain 2010, 6 (1): 16.)
*** Science: Cancer
According to studies conducted at the Catholic University of
Korea, Seoul, a synthetic cannabinoid (in WIN55 ,212-2) inhibits the proliferation of human cells
of stomach cancer in a dose
-dependent effect mediated by the CB1 receptor
. (Source: Xi'an XS, et al. J Cell Biochem 2010 Mar
24. [Electronic publication ahead of print]).
International Association for Cannabinoid Medicines
(IACM)
Am
Mildenweg 6 D-59602 Germany Ruether
Phone: +49 (0) 2952-9708571
Fax: +49 (0) 2952-902651
Email: Info@cannabis-med.org
http://www.cannabis-med.org
To unsubscribe or discharge the mailing list
Bulletin of the IACM, or if you change your address e-mail, please visit
www.cannabis-med.org/spanish/subscribe.htm .
can choose different languages \u200b\u200b(English, German, French, Dutch, Italian and English
).
items taken from the Bulletin of the IACM
can be printed, translated and distributed freely for any purpose
noncommercial, provided the original work is properly cited
. The source of the Bulletin the IACM is
"IACM, www.cannabis-med.org ."
All comments are owned by the authors, the gang is not responsible for the minds of mothers and demands that may cause the comments made ... LosMejoresCuates Copyright 2005-2006 
